CDSCO (India)
NOTICE
Manufacturing and marketing of un-approved drug products containing Enclomiphene and its combinations
Published: 8/11/2026Detected: 8/11/2026
Summary preview
Addresses CDSCO expectations for the manufacturing and marketing of drug products containing enclomiphene and its combinations, specifically highlighting controls around products that are not yet approved.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
safety
labeling
#CDSCO notice
#enclomiphene
#unapproved drug products
#marketing authorization
#manufacturing compliance
Official Source Document Source Verified
Access the original document directly from INDIA CDSCO.
More from CDSCO (India)
- 28.10.2026 G.S.R. 954(E)_Draftâ Amendment of Rule 43A of the Drugs Rules, 1945 to include various ICDs/Port/SEZs for the import of Drugs/ Medical Devices/ Cosmetics in India10/28/2026
- 28.10.2026 G.S.R. 955(E)_Draft Notification for amendment in the Drugs Rules, 1945 for requirement of an authorised person responsible for batch release of product10/28/2026
- 2026.10.28 G.S.R. 951(E)_Notification regarding rationalization of shelf life under Rule 31 of Drugs Rules, 194510/28/2026
- Appointment of Central Compounding Authority Order10/28/2026
- Misleading or false claims of the product FatX solution registered under COS-2 vide RC no. RC/COS-003300 by the firm M/s Tekno Midas Aesthetics10/28/2026